NCT03317327View on ClinicalTrials.gov

REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 9, 2017

Primary Completion Date

November 28, 2022

Study Completion Date

November 28, 2022

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Nivolumab

Nivolumab is a humanized antibody used in cancer immunotherapy.

RADIATION

Radiotherapy (RT)

Radiotherapy (RT) will be given to a total dose of 60 Gy (1,5 Gy fractions twice daily) for a total period of 4 weeks

Trial Locations (1)

Unknown

Oslo University Hospital, Oslo

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Oslo University Hospital

OTHER

NCT03317327 - REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors | Biotech Hunter | Biotech Hunter